Table 1 Demographical profiles and clinical variables at evaluation times in HFEM and CM patients

Age years, mean (SD)

48.9 (11.2)

49.4 (11.2)

Sex % (n females)

78.7 (37)

69.2 (74)

BMI kg/m², median (25th,75th)

22.00 (20.43,23.63)

23.20 (22.00,25.70)

Baseline MOH % (n)

9.7 (10)

90.3 (93)

Treatment % (n Erenumab)

51.1 (24)

62.6 (67)

 Baseline

11.0 (10.0,13.75)

20.0 (16.0,30.0)

 last month

6.0 (4.0,9.0)

9.0 (5.7,14.3)

 follow-up 1 month

9.0 (8.0,11.0)

14.5 (10.0,18.0)

 follow-up 2 month

10.5 (9.2,11.7)

16.0 (10.7,20.0)

 follow-up 3 month

10.5 (9.0,13.5)

15.0 (10.7,22.0)

 last month

−63.6 (−84.7,-60.0)

−61.1   (-77.3, -40.0)

 follow-up 1 month

−42.9 (−87.9,-42.5)

−46.6  (-69.6, -15.4)

 follow-up 2 month

−28.6 (−71.5,–20.5)

−40.0 (-55.6, -10.0)

 follow-up 3 month

−14.3 (−65.9,-10.3)

−30.0   (-55.0, -6.7)

 last month - follow-up 3 difference

−47.7 (−79.5,-17.0)

−25.5 (−47.1,-3.3)

 Baseline

12.0 (10.5,14.5)

21.0 (15.0,32.0)

 last month

4.0 (2.0,7.0)

7.0 (4.0,13.0)

 follow-up 1 month

6.0 (2.5,11.0)

8.0 (5.0,15.0)

 follow-up 2 month

9.0 (5.5,12.5)

12.0 (8.0,18.0)

 follow-up 3 month

10.0 (6.0,13.5)

15.0 (9.0,22.0)

 Baseline

7.5 (7.0,8.0)

7.0 (7.0,8.0)

 last month

6.0 (4.0,6.2)

5.0 (4.0,7.0)

 follow-up 1 month

6.0 (4.7,7.0)

6.0 (4.0,7.0)

 follow-up 2 month

6.0 (4.7,7.0)

6.0 (5.0,7.0)

 follow-up 3 month

7.0 (5.0,7.0)

7.0 (5.0,8.0)

 Baseline

66.5 (64.7,70.0) [33]

67.0 (64.0,72.0) [83]

 last month

51.0 (41.5,60.0) [24]

55.0 (50.0,62.0) [57]

 follow-up 1 month

56.0 (31.5,62.3) [20]

60.0 (53.0,66.0) [51]

 follow-up 2 month

61.5 (51.5,65.0) [22]

62.0 (53.5,66.5) [51]

 follow-up 3 month

60.5 (48.3,65.3) [37]

63.0 (51.0,68.0) [75]